The 23^rd International Congress of the European Society of Toxicology In Vitro (ESTIV 2026) ↗ will take place in the vibrant city of Maastricht from June 29 to July 2, 2026. Centered around the inspiring theme, “Ensuring Safety, Advancing Science: Bridging to the Future with NAMs” the congress aims to explore the transformative impact of New Approach Methodologies (NAMs) in ensuring safety, promoting innovation, and shaping the future of toxicology. 

PARC will be prepresented by: 

• Birgit Mertens (Sciensano ↗, Belgium) presenting a communication entitled Advancing Genotoxicity Assessment for Regulatory Applications by Integrating Transcriptomics with BMD and IVIVE Approaches, 
• Dajana Lichtenstein (BfR ↗, Germany) presenting a poster entitled A 3D Co-Culture Model Simulating the Human Hepatic Microenvironment, 
• Annick Van den Brand (RIVM ↗, Netherlands) presenting a poster entitled Human Relevance Assessment of Adverse Outcome Pathways and Associated NAMs, 
• Luis Antonio Rico Guerrero (RECETOX ↗, Chez Republic) presenting a poster entitled From silence to suspects: investigating cellular dialogue disruption via gap junctions in the detection of non-genotoxic carcinogens, 
• Iva Sovadinova (RECETOX ↗, Chez Republic) presenting a poster entitled Towards serum-free, hormone-controlled culture conditions for in vitro steroidogenesis assays, 
•  Joyce de Paula Souza (University of Basel ↗, Switzerland) presenting a poster entitled Establishment of Readiness Criteria for AI-based tools for risk assessment: READYAI
• Levi Winkelman (Leiden University ↗, the Netherlands) presenting a poster entitled Building a quantitative adverse outcome pathway for AOP #38 – Protein Alkylation Leads to Liver Fibrosis, 
• Janssen Aafke (Wageningen University ↗, the Netherlands) predenting a poster entitled  Setting up new approach methods to study B cell immunotoxicity using peripheral blood mononuclear cells. 

The theme of ESTIV 2026 closely aligns with PARC’s mission to advance innovative approaches for chemical risk assessment and strengthen the scientific basis for regulatory decision-making. Through these presentations, PARC partners will contribute to discussions on the future of toxicology and the integration of NAMs into safety assessment frameworks.